Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation

Biotech SG&A Expenses: A Decade of Strategic Growth

__timestampInsmed IncorporatedVericel Corporation
Wednesday, January 1, 20143107300013774000
Thursday, January 1, 20154321600022479000
Friday, January 1, 20165067900027388000
Sunday, January 1, 20177917100035610000
Monday, January 1, 201816821800049007000
Tuesday, January 1, 201921079600061139000
Wednesday, January 1, 202020361300068836000
Friday, January 1, 202123427300097592000
Saturday, January 1, 2022265784000106903000
Sunday, January 1, 2023344501000120998000
Loading chart...

Unleashing the power of data

Navigating SG&A Expenses: A Tale of Two Biotechs

In the competitive landscape of biotechnology, effective cost management is crucial. Insmed Incorporated and Vericel Corporation, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, reflecting its aggressive growth strategy. In contrast, Vericel's expenses increased by approximately 780%, indicating a more measured expansion.

A Decade of Financial Evolution

In 2014, Insmed's SG&A expenses were just over $31 million, while Vericel's were around $14 million. Fast forward to 2023, and Insmed's expenses have ballooned to $345 million, with Vericel reaching $121 million. This growth underscores the dynamic nature of the biotech industry, where strategic investments in administration and sales can drive significant business transformation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025